Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms.

[1]  D. Mahler,et al.  Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. , 2009, Respiratory medicine.

[2]  D. Tashkin,et al.  Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD , 2009, COPD.

[3]  S. Bollmeier,et al.  Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease , 2008, The Annals of pharmacotherapy.

[4]  A. Sanduzzi,et al.  Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. , 2008, Respiratory medicine.

[5]  C. Vogelmeier,et al.  Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. , 2008, Respiratory medicine.

[6]  M. Littner,et al.  Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. , 2008, Respiratory medicine.

[7]  B. O'connor,et al.  Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD , 2008, Thorax.

[8]  S. Kudoh,et al.  Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD. , 2007, Osaka city medical journal.

[9]  J. Bourbeau,et al.  Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.

[10]  M. Decramer.  Tiotropium as essential maintenance therapy in COPD , 2006, European Respiratory Review.

[11]  J. V. van Noord,et al.  Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. , 2006, Chest.

[12]  H. Meurs,et al.  Protein kinase C potentiates homologous desensitization of the β2-adrenoceptor in bovine tracheal smooth muscle , 2006 .

[13]  H. Meurs,et al.  Protein kinase C potentiates homologous desensitization of the beta2-adrenoceptor in bovine tracheal smooth muscle. , 2006, European journal of pharmacology.

[14]  D. D. Briggs,et al.  Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. , 2005, Pulmonary pharmacology & therapeutics.

[15]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[16]  C. Cooper,et al.  Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease , 2005, BMJ : British Medical Journal.

[17]  W. Bailey,et al.  Maintenance pharmacotherapy of chronic obstructive pulmonary disease: an evidence-based approach , 2005, Expert opinion on pharmacotherapy.

[18]  D. Mahler,et al.  The MCID of the Transition Dyspnea Index is a Total Score of One Unit , 2005, COPD.

[19]  M. Cazzola,et al.  The functional impact of adding salmeterol and tiotropium in patients with stable COPD. , 2004, Respiratory medicine.

[20]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[21]  P. Calverley,et al.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease , 2003, Thorax.

[22]  G. D. Cioppa,et al.  Formoterol Therapy for Chronic Obstructive Pulmonary Disease: A Review of the Literature , 2002, Pharmacotherapy.

[23]  H. Meurs,et al.  Muscarinic receptor-Beta-adrenoceptor cross-talk in airways smooth muscle , 2001 .

[24]  H. Meurs,et al.  Muscarinic Receptors in Airways Diseases , 2001, Progress in Inflammation Research.

[25]  M. Littner,et al.  Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[26]  A. Tobin,et al.  Cross talk between m3-muscarinic and beta(2)-adrenergic receptors at the level of receptor phosphorylation and desensitization. , 1999, Molecular pharmacology.

[27]  F. Maesen,et al.  Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. , 1995, The European respiratory journal.

[28]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[29]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[30]  H. Hayakawa,et al.  Atrial systolic failure in cardiac amyloidosis. , 1993, The New England journal of medicine.

[31]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[32]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[33]  A. Zwinderman,et al.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. , 1992, The New England journal of medicine.

[34]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[35]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.